↑ Read the latest from the desks · fresh intelligence, published daily✦Quiet reading✦No ads, ever✦Ad-free articles read by humans today …↑✦Boards engagement today … people · … AI✦Corporate brand & media services✦Made in Virginia Beach since 1997✦
ResMed's **$41B** cap faces revaluation as strategic review separates respiratory devices from cloud platforms, exploiting **38%** multiple gap before 2026 Medicare cuts.
$41 billion
in market capitalization under scrutiny
140 markets
for sleep apnea and chronic obstructive pulmonary disease devices
1.5 million
active patients across home care networks
18 months
of margin compression in ResMed's Software-as-a-Service segment
ResMed Inc. filed an 8-K material event disclosure signaling a strategic review of its respiratory device and cloud-connected care platforms, placing $41 billion in market capitalization under scrutiny. The San Diego-based manufacturer controls 140 markets for sleep apnea and chronic obstructive pulmonary disease devices, with cloud infrastructure touching 1.5 million active patients across home care networks. The filing arrives as digital health infrastructure faces compression across telehealth and remote monitoring verticals, with connected-device margins under pressure from reimbursement headwinds and hospital capital equipment freezes.
The strategic review follows 18 months of margin compression in ResMed's Software-as-a-Service segment, which posted 11.2% operating margins in the most recent quarter versus 14.8% a year prior. Cloud-connected respiratory platforms now account for $980 million in annual recurring revenue, embedded in hospital discharge protocols and home health networks that face $2.3 billion in annual Medicare Advantage rate cuts effective January 2026. The review encompasses device manufacturing, software licensing, and cloud infrastructure — three verticals that separately command different multiples in the current market. ResMed's respiratory device business trades at 6.8x forward revenue while its SaaS contracts carry 4.2x multiples, a 38% valuation gap that strategic acquirers can arbitrage through structural separation.
Digital health consolidation has accelerated in the past 90 days, with private equity firms and strategic healthcare operators circling assets that carry both regulatory moats and embedded patient networks. ResMed's connected-care platform integrates with 470 hospital systems and feeds data into chronic disease management protocols worth $18 billion annually in the Medicare fee-for-service population. The company's device portfolio holds 340 active patents in non-invasive ventilation and adaptive pressure algorithms, intellectual property that commands premium multiples in medtech M&A. Strategic buyers include Philips, which exited the ventilator market under consent decree in 2023 and now seeks respiratory assets without legacy liability, and private equity infrastructure funds targeting recession-resistant healthcare cash flows with 80%+ gross retention rates.
Allocators should monitor ResMed's December earnings call for formal guidance on the review timeline, with separation or sale likely to surface in Q2 2025. The respiratory device segment generates $3.2 billion in annual revenue with 22% EBITDA margins, defensible in downturn scenarios due to clinical necessity and formulary lock-in. Cloud platform multiples will depend on demonstrated pricing power in the 2026 reimbursement cycle, where home health networks face rate compression but retain volume growth from aging demographics. Private equity interest will show in 13F filings due February 14, particularly from healthcare-focused infrastructure funds that acquired adjacent home medical equipment platforms in the past 24 months.
ResMed's installed base of 6.8 million active devices creates a natural acquirer advantage for operators with existing respiratory supply chains. The strategic review is not distress — it is revaluation arbitrage in a market that misprices bundled verticals.
Branded by POPS4 · proof in 60 seconds
For the principal
Position for separation arbitrage: device business holds recession-resistant formulary lock-in, cloud segment faces Medicare rate pressure through 2026 cycle.
For the operator
Monitor December earnings call for timeline; private equity 13Fs due February 14 will signal infrastructure fund interest in respiratory asset class.
For the house
Huang Goodman long RMD through January earnings; thesis assumes device-platform separation unlocks $8-12/share in sum-of-parts by mid-2025.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.